BMO Capital Initiates Coverage On Ionis Pharmaceuticals with Market Perform Rating, Announces Price Target of $60
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsInitiationPrice Target
BMO Capital analyst David Lebowitz initiates coverage on Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Perform rating and announces Price Target of $60.
BMO Capital analyst David Lebowitz initiates coverage on Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Perform rating and announces Price Target of $60.